Trillium Therapeutics Profit Margin

The latest profit margin for TRIL is 151351.16% as of September 2021. That compares with -89801.67% in the prior-year period — up 268.5% year over year. That is above the Healthcare sector average of 14.41%. Investors often review this figure alongside Trillium Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TRIL's profit margin moved from -89801.67% to 151351.16% — a 268.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Trillium Therapeutics's valuation or profitability profile.

Against Healthcare companies, TRIL currently prints 151351.16% for profit margin, while the sector average sits near 14.41%. That is roughly 1049871.8% above the sector mean. Large gaps often invite a closer look at Trillium Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Trillium Therapeutics converts resources into returns. At 151351.16%, TRIL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -89801.67% in the prior-year period — up 268.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TRIL's profit margin (151351.16%), review year-over-year change from -89801.67%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.